
April 2 (Reuters) - Quoin Pharmaceuticals Ltd 2EBy.BE:
QUOIN PHARMACEUTICALS ANNOUNCES ADDITIONAL POSITIVE ‘WHOLE BODY’ CLINICAL DATA FROM ONGOING PEDIATRIC NETHERTON SYNDROME STUDY AND APPROVAL TO INITIATE TESTING OF A SECOND PEDIATRIC PATIENT
QUOIN PHARMACEUTICALS LTD - SUBJECT'S SKIN ALMOST COMPLETELY HEALED AFTER 6 WEEKS OF QRX003
QUOIN PHARMACEUTICALS LTD - NO ADVERSE EVENTS REPORTED AFTER 6 WEEKS OF QRX003 TREATMENT
Further company coverage: [2EBy.BE]